Compare Protagonist Therapeutics, Inc. (PTGX) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock

Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 32.4x trailing P/E (25.7x forward), making it the more compelling value choice. Analysts rate Protagonist Therapeutics, Inc. (PTGX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Protagonist Therapeutics, Inc. is actually cheaper at 25.4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Protagonist Therapeutics, Inc. (PTGX) delivered a total return of +244.2%, compared to +136.2% for Vertex Pharmaceuticals Incorporated (VRTX). A $10,000 investment in PTGX five years ago would be worth approximately $34K today (assuming dividends reinvested). Over 10 years, the gap is even starker: PTGX returned +687.0% versus VRTX's +481.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc. (PTGX) is the lower-risk stock at -0.11β versus Vertex Pharmaceuticals Incorporated's 0.44β — meaning VRTX is approximately -504% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 20% for Vertex Pharmaceuticals Incorporated — giving it more financial flexibility in a downturn.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus 0.0% for Protagonist Therapeutics, Inc. — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus 0.0% for PTGX. At the gross margin level — before operating expenses — VRTX leads at 86.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Protagonist Therapeutics, Inc. (PTGX) trades at 25.4x forward P/E versus 25.7x for Vertex Pharmaceuticals Incorporated — 0.2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PTGX: 21.4% to $111.75.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc. (PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.11), +687.0% 10Y return). Both have compounded well over 10 years (PTGX: +687.0%, VRTX: +481.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.